Hypermarcas (OTCMKTS:HYPMY) Issues Earnings Results

Hypermarcas (OTCMKTS:HYPMY) announced its earnings results on Wednesday. The company reported $0.15 EPS for the quarter, beating analysts’ consensus estimates of $0.14 by $0.01, Zacks reports. Hypermarcas had a return on equity of 12.68% and a net margin of 19.77%. The business had revenue of $473.13 million during the quarter, compared to analysts’ expectations of $450.75 million.

Hypermarcas Stock Performance

OTCMKTS HYPMY traded down $0.10 during trading on Thursday, reaching $3.98. The company’s stock had a trading volume of 70,030 shares, compared to its average volume of 46,671. The business’s fifty day moving average price is $4.63 and its 200-day moving average price is $4.41. Hypermarcas has a twelve month low of $3.39 and a twelve month high of $5.77. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.26 and a current ratio of 1.86. The firm has a market cap of $2.80 billion, a price-to-earnings ratio of 7.96 and a beta of 0.78.

Analysts Set New Price Targets

Separately, Jefferies Financial Group raised shares of Hypermarcas to a “strong-buy” rating in a research note on Monday, July 20th. One analyst has rated the stock with a Strong Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy”.

About Hypermarcas

Hypermarcas was a Brazilian consumer-products and pharmaceutical company that later adopted the name Hypera Pharma. The company refocused its operations on pharmaceuticals after divesting a number of businesses in other consumer-goods categories. Today, Hypera Pharma develops, manufactures and markets medicines in Brazil, including prescription drugs, over-the-counter products and branded generics. Its portfolio also includes vitamins and supplements, and it sells products under brands such as Neo Química and Mantecorp.